JP2020520988A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520988A5 JP2020520988A5 JP2020504095A JP2020504095A JP2020520988A5 JP 2020520988 A5 JP2020520988 A5 JP 2020520988A5 JP 2020504095 A JP2020504095 A JP 2020504095A JP 2020504095 A JP2020504095 A JP 2020504095A JP 2020520988 A5 JP2020520988 A5 JP 2020520988A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- substituted
- optionally
- alkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003118 aryl group Chemical group 0.000 claims 50
- 150000001875 compounds Chemical class 0.000 claims 40
- 125000006693 (C2-C9) heterocyclyl group Chemical group 0.000 claims 38
- 125000001072 heteroaryl group Chemical group 0.000 claims 34
- 238000004132 cross linking Methods 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 31
- 125000004452 carbocyclyl group Chemical group 0.000 claims 28
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 20
- 229910052736 halogen Inorganic materials 0.000 claims 20
- 150000002367 halogens Chemical class 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 20
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 125000002887 hydroxy group Chemical class [H]O* 0.000 claims 19
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 17
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 16
- 150000003573 thiols Chemical class 0.000 claims 13
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- -1 hydroxy, amino Chemical group 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 125000005647 linker group Chemical group 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 150000002825 nitriles Chemical class 0.000 claims 5
- 108010020062 Peptidylprolyl Isomerase Proteins 0.000 claims 4
- 102000009658 Peptidylprolyl Isomerase Human genes 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 108010068682 Cyclophilins Proteins 0.000 claims 3
- 102000001493 Cyclophilins Human genes 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 102100037827 Peptidyl-prolyl cis-trans isomerase D Human genes 0.000 claims 2
- 102100020739 Peptidyl-prolyl cis-trans isomerase FKBP4 Human genes 0.000 claims 2
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims 2
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- 101150093441 CYP40 gene Proteins 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 102100038912 E3 SUMO-protein ligase RanBP2 Human genes 0.000 claims 1
- 108010069271 FKBP-13 Proteins 0.000 claims 1
- 101000896726 Homo sapiens Lanosterol 14-alpha demethylase Proteins 0.000 claims 1
- 101000979578 Homo sapiens NK-tumor recognition protein Proteins 0.000 claims 1
- 101100137375 Homo sapiens PPID gene Proteins 0.000 claims 1
- 101000611202 Homo sapiens Peptidyl-prolyl cis-trans isomerase B Proteins 0.000 claims 1
- 101000687115 Homo sapiens Peptidyl-prolyl cis-trans isomerase C Proteins 0.000 claims 1
- 101000827313 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP3 Proteins 0.000 claims 1
- 101000932178 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP4 Proteins 0.000 claims 1
- 101000878253 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP5 Proteins 0.000 claims 1
- 101001091194 Homo sapiens Peptidyl-prolyl cis-trans isomerase G Proteins 0.000 claims 1
- 101000741800 Homo sapiens Peptidyl-prolyl cis-trans isomerase H Proteins 0.000 claims 1
- 101000741830 Homo sapiens Peptidyl-prolyl cis-trans isomerase-like 1 Proteins 0.000 claims 1
- 101000620711 Homo sapiens Peptidyl-prolyl cis-trans isomerase-like 4 Proteins 0.000 claims 1
- 101001091544 Homo sapiens Peptidylprolyl isomerase domain and WD repeat-containing protein 1 Proteins 0.000 claims 1
- 101001123267 Homo sapiens Probable inactive peptidyl-prolyl cis-trans isomerase-like 6 Proteins 0.000 claims 1
- 101000574242 Homo sapiens RING-type E3 ubiquitin-protein ligase PPIL2 Proteins 0.000 claims 1
- 101000595252 Homo sapiens Serine/threonine-protein phosphatase PP1-alpha catalytic subunit Proteins 0.000 claims 1
- 101000889087 Homo sapiens Spliceosome-associated protein CWC27 homolog Proteins 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 101100061197 Mus musculus Cyp27b1 gene Proteins 0.000 claims 1
- 108010059419 NIMA-Interacting Peptidylprolyl Isomerase Proteins 0.000 claims 1
- 102100023384 NK-tumor recognition protein Human genes 0.000 claims 1
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 claims 1
- 102100024968 Peptidyl-prolyl cis-trans isomerase C Human genes 0.000 claims 1
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 claims 1
- 102100027914 Peptidyl-prolyl cis-trans isomerase FKBP1B Human genes 0.000 claims 1
- 102100026408 Peptidyl-prolyl cis-trans isomerase FKBP2 Human genes 0.000 claims 1
- 102100023846 Peptidyl-prolyl cis-trans isomerase FKBP3 Human genes 0.000 claims 1
- 102100034850 Peptidyl-prolyl cis-trans isomerase G Human genes 0.000 claims 1
- 102100038827 Peptidyl-prolyl cis-trans isomerase H Human genes 0.000 claims 1
- 102100026114 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 Human genes 0.000 claims 1
- 102100038802 Peptidyl-prolyl cis-trans isomerase-like 1 Human genes 0.000 claims 1
- 102100022943 Peptidyl-prolyl cis-trans isomerase-like 4 Human genes 0.000 claims 1
- 102100034852 Peptidylprolyl isomerase domain and WD repeat-containing protein 1 Human genes 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 102100029025 Probable inactive peptidyl-prolyl cis-trans isomerase-like 6 Human genes 0.000 claims 1
- 102100025781 RING-type E3 ubiquitin-protein ligase PPIL2 Human genes 0.000 claims 1
- 101100222695 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CPR5 gene Proteins 0.000 claims 1
- 102100036033 Serine/threonine-protein phosphatase PP1-alpha catalytic subunit Human genes 0.000 claims 1
- 102100039430 Spliceosome-associated protein CWC27 homolog Human genes 0.000 claims 1
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 claims 1
- 150000001350 alkyl halides Chemical class 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002118 epoxides Chemical class 0.000 claims 1
- UCUUFSAXZMGPGH-UHFFFAOYSA-N penta-1,4-dien-3-one Chemical compound C=CC(=O)C=C UCUUFSAXZMGPGH-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 101150108030 ppiD gene Proteins 0.000 claims 1
- 108010062219 ran-binding protein 2 Proteins 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 108010029517 tacrolimus binding protein 1B Proteins 0.000 claims 1
- 108010067247 tacrolimus binding protein 4 Proteins 0.000 claims 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 1
- 125000005490 tosylate group Chemical group 0.000 claims 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023101616A JP7781821B2 (ja) | 2017-04-05 | 2023-06-21 | タンパク質－タンパク質界面を分析するための方法及び試薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482018P | 2017-04-05 | 2017-04-05 | |
| US62/482,018 | 2017-04-05 | ||
| PCT/US2018/026014 WO2018187423A1 (en) | 2017-04-05 | 2018-04-04 | Methods and reagents for analyzing protein-protein interfaces |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023101616A Division JP7781821B2 (ja) | 2017-04-05 | 2023-06-21 | タンパク質－タンパク質界面を分析するための方法及び試薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020520988A JP2020520988A (ja) | 2020-07-16 |
| JP2020520988A5 true JP2020520988A5 (enExample) | 2021-05-13 |
Family
ID=63712343
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504095A Pending JP2020520988A (ja) | 2017-04-05 | 2018-04-04 | タンパク質−タンパク質界面を分析するための方法及び試薬 |
| JP2023101616A Active JP7781821B2 (ja) | 2017-04-05 | 2023-06-21 | タンパク質－タンパク質界面を分析するための方法及び試薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023101616A Active JP7781821B2 (ja) | 2017-04-05 | 2023-06-21 | タンパク質－タンパク質界面を分析するための方法及び試薬 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20210285955A1 (enExample) |
| EP (1) | EP3607326A4 (enExample) |
| JP (2) | JP2020520988A (enExample) |
| KR (2) | KR20240093922A (enExample) |
| CN (1) | CN110785428A (enExample) |
| AU (2) | AU2018250186B2 (enExample) |
| BR (1) | BR112019020967A2 (enExample) |
| CA (1) | CA3058964A1 (enExample) |
| IL (1) | IL269779B1 (enExample) |
| WO (1) | WO2018187423A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116478132A (zh) | 2016-07-12 | 2023-07-25 | 锐新医药公司 | 作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪 |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| TWI852912B (zh) | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| CA3078565A1 (en) | 2017-10-12 | 2019-04-18 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| AU2019401466B2 (en) * | 2018-12-21 | 2025-04-24 | Revolution Medicines, Inc. | Compounds that participate in cooperative binding and uses thereof |
| CA3159559A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN114867735A (zh) | 2019-11-04 | 2022-08-05 | 锐新医药公司 | Ras抑制剂 |
| KR20250175006A (ko) | 2019-11-04 | 2025-12-15 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN119661684B (zh) * | 2024-10-21 | 2025-11-25 | 山东大学 | 一种高抗炎活性的脂联素突变体及其制备方法与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999010373A1 (en) * | 1997-08-26 | 1999-03-04 | Wisconsin Alumni Research Foundation | Non-immunosuppressive cyclosporins and their use in the prevention and treatment of hiv infection |
| US7220552B1 (en) * | 1999-11-19 | 2007-05-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and their use in the disruption of protein-protein interactions |
| US7176037B2 (en) * | 2000-07-13 | 2007-02-13 | The Scripps Research Institute | Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation |
| US8324262B2 (en) * | 2005-12-20 | 2012-12-04 | The Brigham And Women's Hospital, Inc. | Tricyclic necrostatin compounds |
| CN101351550B (zh) * | 2006-01-03 | 2012-10-10 | 霍夫曼-拉罗奇有限公司 | 具有卓越的伴侣和折叠活性的嵌合融合蛋白 |
| US20090054334A1 (en) * | 2007-05-23 | 2009-02-26 | Mutz Mitchell W | Combinatorial improvement of bifunctional drug properties |
| US9428845B1 (en) * | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
| US9260484B2 (en) * | 2011-06-15 | 2016-02-16 | Ohio State Innovation Foundation | Small molecule composite surfaces as inhibitors of protein-protein interactions |
| TW201629069A (zh) * | 2015-01-09 | 2016-08-16 | 霍普驅動生物科技股份有限公司 | 參與協同結合之化合物及其用途 |
| US10427131B2 (en) * | 2015-03-19 | 2019-10-01 | 3M Innovative Properties Company | Guanidine-functionalized perlite particles, articles containing the particles, and methods of using the particles and articles |
| US9989535B2 (en) * | 2015-10-01 | 2018-06-05 | Warp Drive Bio, Inc. | Methods and reagents for analyzing protein-protein interfaces |
| CN105902537A (zh) * | 2016-04-26 | 2016-08-31 | 兰州大学 | 靶向人fkbp51蛋白的先导化合物及其筛选方法与应用 |
| EP3606492A4 (en) * | 2017-04-05 | 2020-11-11 | Revolution Medicines, Inc. | LINKS INVOLVED IN A COOPERATIVE BINDING AND USES THEREOF |
-
2018
- 2018-04-04 WO PCT/US2018/026014 patent/WO2018187423A1/en not_active Ceased
- 2018-04-04 CA CA3058964A patent/CA3058964A1/en active Pending
- 2018-04-04 EP EP18781381.1A patent/EP3607326A4/en active Pending
- 2018-04-04 KR KR1020247017424A patent/KR20240093922A/ko not_active Ceased
- 2018-04-04 CN CN201880037176.0A patent/CN110785428A/zh active Pending
- 2018-04-04 US US16/500,634 patent/US20210285955A1/en not_active Abandoned
- 2018-04-04 BR BR112019020967-0A patent/BR112019020967A2/pt unknown
- 2018-04-04 KR KR1020197032295A patent/KR20200003802A/ko not_active Ceased
- 2018-04-04 AU AU2018250186A patent/AU2018250186B2/en active Active
- 2018-04-04 JP JP2020504095A patent/JP2020520988A/ja active Pending
-
2019
- 2019-10-03 IL IL269779A patent/IL269779B1/en unknown
-
2023
- 2023-06-21 JP JP2023101616A patent/JP7781821B2/ja active Active
-
2024
- 2024-02-22 US US18/584,357 patent/US20240426833A1/en active Pending
- 2024-11-19 AU AU2024266705A patent/AU2024266705A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520988A5 (enExample) | ||
| JP2019501863A5 (enExample) | ||
| US20220403052A1 (en) | Anti-dll4/vegf dual variable domain immmunoglobulin and uses thereof | |
| JP2017505622A5 (enExample) | ||
| Oostendorp et al. | The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib | |
| JP2015529208A5 (enExample) | ||
| ES2856482T3 (es) | Combinaciones de inhibidores de FGFR y cMet para el tratamiento del cáncer | |
| BR112021005606A2 (pt) | processo de produção de um composto para inibir a atividade de shp2 | |
| SG11201408279QA (en) | Social sharing of security information in a group | |
| JP2015508757A5 (enExample) | ||
| SI2797918T1 (en) | Bromodomain inhibitors | |
| JP2021138726A (ja) | ラパフシン・ライブラリの合成と組成物 | |
| HRP20180443T1 (hr) | Povezujuće domene usmjerene protiv gpcr-a: g proteinski kompleksi i njihove derivirane uporabe | |
| EP2650009A3 (en) | Screening methods using G-protein coupled receptors and related compositions | |
| WO2016180765A1 (en) | Anti-fcrn antibodies | |
| EA201290172A1 (ru) | Стабильные полипептиды, вариабельные домены антитела и антагонисты против tnfr1 | |
| Iwai et al. | Utility of P-glycoprotein and organic cation transporter 1 double-transfected LLC-PK1 cells for studying the interaction of YM155 monobromide, novel small-molecule survivin suppressant, with P-glycoprotein | |
| JP2016510309A5 (enExample) | ||
| JP2005528341A5 (enExample) | ||
| J Macdonald et al. | A unique industrial–academic collaboration towards the next generation of schizophrenia therapeutics | |
| Kane et al. | Identification of novel allosteric modulator binding sites in NMDA receptors: a molecular modeling study | |
| Jansen et al. | Constant-pH molecular dynamics simulations of progressive activation in a proton-gated ion channel | |
| JP2010540660A5 (enExample) | ||
| WO2006107941A1 (en) | DERIVATIVES OF [6,7-DIHYDRO-5HIMIDAZO [l,2-ALPHA] IMIDAZOLE-3-SULFONYL]-AZETEDINE-CARBOXYLIC ACIDS, ESTERS AND AMIDES AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | |
| Bock et al. | Calcium waves, gradients and oscillations |